ReviewInternational immunopharmacology2020
Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics.
Review in International immunopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Toll-Like Receptor Dysregulation in The Hospitalized COVID-19 Patients.Advanced biomedical research · 2025Article
- Effect of treatment regimen of the rheumatoid arthritis patients on the risk of coronavirus disease 2019 by modulating the inflammatory mediators.Inflammopharmacology · 2023Article
- HLA-B27 did not protect against COVID-19 in patients with axial spondyloarthritis - data from the ReumaCov-Brasil Registry.Advances in rheumatology (London, England) · 2023Article
- Evaluation of the relationship between serum interleukin-1β levels and expression of inflammasome-related genes in patients with COVID-19.BMC immunology · 2023Article
- The prevalence and contributing risk factors of coronavirus disease 2019 infection in patients with metabolic syndrome.BMC endocrine disorders · 2023Article
- A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia.Vaccines · 2023Review
- Study on the cytokines related to SARS-Cov-2 in testicular cells and the interaction network between cells based on scRNA-seq data.Open life sciences · 2023Article
- mRNA expression of toll-like receptors 3, 7, 8, and 9 in the nasopharyngeal epithelial cells of coronavirus disease 2019 patients.BMC infectious diseases · 2022Article
- The prognostic value of S100A calcium binding protein family members in predicting severe forms of COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Article
- Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019.International immunopharmacology · 2021Article
- Human genetic basis of coronavirus disease 2019.Signal transduction and targeted therapy · 2021Review
- Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update.Infectious diseases (London, England) · 2021Article
- The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses.IUBMB life · 2021Review
- Review
- Differentially expressed immune response genes in COVID-19 patients based on disease severity.Aging · 2021Article
- Pathogenesis and Mechanism of Gastrointestinal Infection With COVID-19.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) is responsible for recent ongoing public health emergency in the world. Sharing structural and behavioral similarities with its ancestors [SARS and Middle East Respiratory Syndrome (MERS)], SARS-CoV-2 has lower fatality but faster transmission. We have gone through a long path to recognize SARS and MERS, therefore our knowledge regarding SARS-CoV-2 is not raw. Various responses of the immune system account for the wide spectrum of clinical manifestations in Coronavirus disease-2019 (COVID-19). Given the innate immune response as the front line of defense, it is immediately activated after the virus entry. Consequently, adaptive immune response is activated to eradicate the virus. However, this does not occur in every case and immune response is the main culprit causing the pathological manifestations of COVID-19. Lethal forms of the disease are correlated with inefficient and/or insufficient immune responses associated with cytokine storm. Current therapeutic approach for COVID-19 is in favor of suppressing extreme inflammatory responses, while maintaining the immune system alert and responsive against the virus. This could be contributing along with administration of antiviral drugs in such patients. Furthermore, supplementation with different compounds, such as vitamin D, has been tested to modulate the immune system responses. A thorough understanding of chronological events in COVID-19 contributing to the development of a highly efficient treatment has not figured out yet. This review focuses on the virus-immune system interaction as well as currently available and potential therapeutic approaches targeting immune system in the treatment of COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.